Troche
Apomorphine / Sildenafil / Tadalafil / Vardenafil Troches
Quad-mix troche combining three PDE5 inhibitors with apomorphine dopamine agonist for maximum potency and comprehensive mechanism.
4, 8 or 12 troches per month
Starting at $69/mo
Research peptideSexual wellnessDesire
PT-141 (Bremelanotide)
RxPrescription onlyInjected under the skin · Once a day · 0.2 mg · Research peptide · Sexual wellness · Desire
Starting at $159/mo
PT-141 (bremelanotide): a melanocortin receptor agonist approved as Vyleesi for low sexual desire in women; used off-label in men. Subcutaneous injection 2–4 hours before sex. Common side effect: nausea. Not for uncontrolled high blood pressure.
Choose your plan
Real prices from our pharmacy. Longer plans cost less per month and are billed up front. Pause or cancel anytime.
- Approved for low sexual desire in women (Vyleesi); off-label in men
- On-demand dosing: inject 2–4 hours before sex, no daily pill needed
- Significant boost in sexual interest and arousal for many users
Every plan includes
- Personalized, physician-guided plan
- Monthly, 3-month and 6-month plans
- Dispensed by a US-licensed compounding pharmacy
- Unlimited protocol adjustments and messaging
- Ongoing support and check-ins
- Pause or cancel anytime
- Reviewed by our in-house physicians
- Physician-guided care
- Ongoing, expert support
- 100% online
- Free, discreet shipping
What is PT-141?
(bremelanotide; melanocortin receptor agonist)
PT-141 (bremelanotide) is a melanocortin receptor agonist that increases sexual interest and arousal by activating receptors in the brain and body. It is FDA-approved as Vyleesi for women with hypoactive sexual desire disorder (HSDD). It is used off-label in men with low desire. Given as a subcutaneous injection 2–4 hours before sexual activity, PT-141 does not require daily dosing. Common side effect: nausea in the first hours (30–50% of users), often mild but sometimes requiring an antiemetic.
- How it is taken
- Injected under the skin
- How often
- Once a day
- Dose range
- 0.2 mg
- Form
- Research peptide · Sexual wellness · Desire
FDA-approved
for women with HSDD (Vyleesi); off-label use in men
PT-141 works for sexual interest; arousal and response still depend on desire and stimulation. It is not prescribed with uncontrolled high blood pressure (melanocortin agonists can raise BP). Nausea is common but usually mild.
How it works,
week by week.
Day 1
A US-licensed physician reviews your goals, medical history, and medications. Your BP and cardiac history are checked.
Week 1
The first dose is tested privately to confirm tolerance and response.
Week 2–4
Sexual interest and arousal increase predictably on-demand.
Month 2
Your physician checks in: PT-141 users discuss sexual satisfaction and any side effects.
Beyond
Use as-needed; your physician reviews annually or if changes occur.
What you may notice,
and when.
Sexual interest
on-demand boost in desire and arousal
Confidence
improves confidence in intimacy
Safety monitoring required
blood pressure and cardiac history
Individual results vary. Benefits reflect what Zepym Health members commonly report to their physician at check-ins; they are not the results of a clinical trial.
Safety first:
what to know before you start.
Important safety information and common side effects
PT-141 activates melanocortin receptors in the brain and body. Nausea is common (30–50%), usually mild; do not use with uncontrolled high blood pressure, recent MI, unstable angina, or severe heart disease. In men, priapism (erection lasting >4 hours) is rare but requires immediate care. Tell your physician about blood pressure medications, heart history, and any skin concerns. Stop and seek care for severe headache, chest pain, priapism, severe nausea, or signs of allergic reaction.
The research behind
PT-141.
PT-141, also called bremelanotide, acts on the desire pathway in the brain. Its one labeled use is for premenopausal women with low desire. The evidence in men is small and early.
- Women's desire0.30 and 0.42 points
Two identical 24-week trials in 1,267 premenopausal women with low desire, using bremelanotide 1.75 mg as needed against placebo. Desire rose 0.30 points more than placebo in one trial and 0.42 in the other. The effects are small.
Kingsberg et al., Obstetrics and Gynecology 2019 - Men, nasalsmall early study
Diamond et al. tested intranasal PT-141 in healthy men and in men with mild-to-moderate erectile dysfunction, measuring erections with RigiScan. It was a small early safety, pharmacokinetic and pharmacodynamic study, not a phase 3 trial.
Diamond et al., International Journal of Impotence Research 2004 - Men, under the skinno trial in men
We found no published phase 3 trial of PT-141 for erectile dysfunction in men. The product sold here is 0.2 mg per dose, a lower dose than the 1.75 mg studied in women, and it has no trial of its own.
PubMed search, bremelanotide and erectile dysfunction (2026)
What the studies found
- Desire rose 0.30 and 0.42 points more than placebo in two 24-week trials of 1,267 premenopausal women with low desire (Kingsberg et al., Obstetrics and Gynecology 2019)
- Distress about low desire fell 0.37 and 0.29 points more than placebo in the same two trials (Kingsberg et al., Obstetrics and Gynecology 2019)
- FDA-labeled for premenopausal women with acquired, generalized hypoactive sexual desire disorder (VYLEESI prescribing information)
Trial figures are for bremelanotide 1.75 mg given under the skin in women. The PT-141 dispensed here is 0.2 mg per dose, a different dose with no trial of its own. Nausea, flushing, headache and vomiting were common in the women's trials.
What this does not say
- The women's trial effects are modest, and they are averages across groups.
- No human trial supports the 0.2 mg dose sold here.
- The label warns that the drug transiently raises blood pressure; the prescriber checks cardiovascular history before any prescription.
The research
behind it.
In trials of women with HSDD, PT-141 significantly increased sexual desire, arousal, and satisfaction compared to placebo. About 40% of women showed meaningful benefit.
Off-label use in men for low desire is growing; evidence is anecdotal and from small studies. Your physician discusses realistic expectations: PT-141 does not overcome relationship problems or performance anxiety alone.
Erections as a vital sign:
what the cohorts showWhy a change in erections is worth a heart check, what the numbers say, and what they do not.Read the researchPDE5 inhibitors:
what the trials showSildenafil, tadalafil and vardenafil compared, daily and as-needed use, and the rule on nitrates.Read the research
what the cohorts showWhy a change in erections is worth a heart check, what the numbers say, and what they do not.Read the researchPDE5 inhibitors:
what the trials showSildenafil, tadalafil and vardenafil compared, daily and as-needed use, and the rule on nitrates.Read the research
Getting started
takes a few minutes.
- 1
Connect with a physician
Answer a few questions online and a US-licensed physician reviews your health, history and goals to make sure treatment is right for you. 100% online. No in-person visit required.
- 2
Get your discreet shipment
If approved, your treatment is compounded by a US-licensed, LegitScript-certified pharmacy, inspected for quality, and shipped discreetly to your door.
- 3
Receive continuous support
Start with one goal, then keep building over time. Unlimited physician messaging, easy refills and dose adjustments, all from the Zepym Health app.
Frequently asked questions
Contact supportHow do I use PT-141?
Injected under the skin, once a day. The starting prescription is 10 units (0.2 mg) each time. Your physician sets your own dose and it is printed on your label.
How much arrives in each shipment?
1 vial at the starting strength, shipped to your door from a licensed US pharmacy.
How do I use PT-141?
Inject subcutaneously 2–4 hours before anticipated sexual activity. Effects peak around 1–2 hours after injection and last several hours. One dose per 24 hours maximum. If nausea occurs, taking an anti-nausea medication (like ondansetron) 30 minutes before PT-141 helps some people. Eat a light meal beforehand; a full meal can delay effects.
How long until I see results?
PT-141: sexual effects appear within 1–2 hours of injection, peak around 2 hours, last several hours. Results require dosing each time you want the effect.
What if I have side effects?
PT-141: nausea is common (30–50%); anti-nausea medication beforehand helps. Rare: priapism in men (erection >4 hours)—seek emergency care. Stop immediately if any severe reaction occurs.
Can I use these with other medications?
Tell your physician about all medications, especially blood pressure drugs or cardiac medications. Some combinations need monitoring.
How long do I use these?
PT-141: as-needed indefinitely, or until your sexual health goals change. Annual check-ins with your physician are recommended.
PT-141 educational content reviewed by our physician
Scott Nass, MD Doctor of Medicine, board-certified in Family Medicine
Charles R. Drew University and David Geffen School of Medicine at UCLA. Family Medicine residency at Ventura County Medical Center.
More options
in this area.
Injection
Bi-Mix Injection
Combination of papaverine and phentolamine for intracavernosal injection. Vasodilator mix for erectile dysfunction. Priapism risk and rescue requirements.
Starting at $171/mo
Cream
Climax Cream
Topical cream for female sexual enhancement and orgasm support. Combination of arginine, ergoloid, pentoxifylline, sildenafil, and theophylline.
Starting at $116/mo
Cream
Ecstasy Cream for Her
Topical cream for female sexual arousal and pleasure. Contains oxytocin, theophylline, arginine, and sildenafil for enhanced sensation and response.
Starting at $138/mo
References
- 1.Bremelanotide for hypoactive sexual desire disorder in women: a randomized, placebo-controlled trial. Obstet Gynecol, 2018
Prescription products require an online evaluation with a licensed medical professional who will determine if a prescription is appropriate. Products are compounded by a licensed pharmacy. The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality. Compounded medications are not FDA-approved brand-name products.